Marsh S, McLeod H L
Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8069, the Siteman Cancer Center, and the CREATE Pharmacogenetic Research Network, St Louis, MO 63110-1093, USA.
Br J Cancer. 2004 Jan 12;90(1):8-11. doi: 10.1038/sj.bjc.6601487.
The large number of active combination chemotherapy regimens for most cancers has led to the need for better information to guide the 'standard' treatment for each patient. In an attempt to individualise therapy, pharmacogenetics and pharmacogenomics (a polygenic approach to pharmacogenetic studies) encompass the search for answers to the hereditary basis for interindividual differences in drug response. This review will focus on the results of studies assessing the effects of polymorphisms in drug-metabolising enzymes and drug targets on the toxicity and response to commonly used chemotherapy drugs. In addition, the need for polygenic pharmacogenomic strategies to identify patients at risk for adverse drug reactions will be highlighted.
针对大多数癌症的大量有效的联合化疗方案，使得人们需要更好的信息来指导针对每位患者的“标准”治疗。为了实现个体化治疗，药物遗传学和药物基因组学（药物遗传学研究的多基因方法）致力于探寻药物反应个体差异的遗传基础。本综述将聚焦于评估药物代谢酶和药物靶点的多态性对常用化疗药物毒性及反应影响的研究结果。此外，还将强调采用多基因药物基因组学策略来识别药物不良反应风险患者的必要性。
